Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab cardiac dysfunction predictor study in HER2-positive breast cancer
2010-019195-67Phase 4Active
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab in breast cancer (2 cohorts), sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoints: Changes in tissue Doppler imaging cardiac parameters predictive of cardiac damage, Early cardiac damage induced by trastuzumab detected by tissue Doppler imaging and 1 more. Started Apr 2010; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019195-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019195-67.